deltatrials
Terminated PHASE2 NCT00210028

Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

Open, Single-Arm Phase II Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer Expressing the Estrogen and/or Progesterone Receptor

Sponsor: Institut Claudius Regaud

Conditions Breast Neoplasms
Interventions Tamoxifen Zarnestra
Updated 5 times since 2017 Last updated: Nov 10, 2006 Started: Aug 31, 2003 Completion: Aug 31, 2008

A PHASE2 clinical study on Breast Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Institut Claudius Regaud and has accumulated 5 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut Claudius Regaud
  • Janssen-Cilag Ltd.
Data source: Institut Claudius Regaud

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bordeaux, France
  • • Montpellier, France
  • • Toulouse, France